Medicine guide
Fablyn
·
- Prescription status not stated
- Urinary and reproductive system, hormones
- Active substance
- Lasofoxifene
- Made by
- Dr. Friedrich Eberth Arzneimittel GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Fablyn is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. A significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated (see section 5.1). When determining the choice of Fablyn or other therapies, including oestrogens, for a postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Dr. Friedrich Eberth Arzneimittel GmbH |
|---|---|
| Active substance | Lasofoxifene |
| Used in | Urinary and reproductive system, hormones |
| Classification | G03 · Urinary and reproductive system, hormones |
| Authorised on | 2009-02-24 |
| Last updated by the regulator | 2012-06-21 |
| EMA product number | EMEA/H/C/000977 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).